321 related articles for article (PubMed ID: 15639191)
1. Prediction of neuropathology in mucopolysaccharidosis I patients.
Fuller M; Brooks DA; Evangelista M; Hein LK; Hopwood JJ; Meikle PJ
Mol Genet Metab; 2005 Jan; 84(1):18-24. PubMed ID: 15639191
[TBL] [Abstract][Full Text] [Related]
2. Glycosaminoglycan degradation fragments in mucopolysaccharidosis I.
Fuller M; Meikle PJ; Hopwood JJ
Glycobiology; 2004 May; 14(5):443-50. PubMed ID: 14718373
[TBL] [Abstract][Full Text] [Related]
3. Identification and molecular characterization of alpha-L-iduronidase mutations present in mucopolysaccharidosis type I patients undergoing enzyme replacement therapy.
Yogalingam G; Guo XH; Muller VJ; Brooks DA; Clements PR; Kakkis ED; Hopwood JJ
Hum Mutat; 2004 Sep; 24(3):199-207. PubMed ID: 15300847
[TBL] [Abstract][Full Text] [Related]
4. alpha-L-iduronidase premature stop codons and potential read-through in mucopolysaccharidosis type I patients.
Hein LK; Bawden M; Muller VJ; Sillence D; Hopwood JJ; Brooks DA
J Mol Biol; 2004 Apr; 338(3):453-62. PubMed ID: 15081804
[TBL] [Abstract][Full Text] [Related]
5. Prediction of Sanfilippo phenotype severity from immunoquantification of heparan-N-sulfamidase in cultured fibroblasts from mucopolysaccharidosis type IIIA patients.
Perkins KJ; Muller V; Weber B; Hopwood JJ
Mol Genet Metab; 2001 Aug; 73(4):306-12. PubMed ID: 11509012
[TBL] [Abstract][Full Text] [Related]
6. A common mutation for mucopolysaccharidosis type I associated with a severe Hurler syndrome phenotype.
Scott HS; Litjens T; Hopwood JJ; Morris CP
Hum Mutat; 1992; 1(2):103-8. PubMed ID: 1301196
[TBL] [Abstract][Full Text] [Related]
7. Residual α-L-iduronidase activity in fibroblasts of mild to severe Mucopolysaccharidosis type I patients.
Oussoren E; Keulemans J; van Diggelen OP; Oemardien LF; Timmermans RG; van der Ploeg AT; Ruijter GJ
Mol Genet Metab; 2013 Aug; 109(4):377-81. PubMed ID: 23786846
[TBL] [Abstract][Full Text] [Related]
8. Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical, and biological implications.
Scott HS; Bunge S; Gal A; Clarke LA; Morris CP; Hopwood JJ
Hum Mutat; 1995; 6(4):288-302. PubMed ID: 8680403
[TBL] [Abstract][Full Text] [Related]
9. Enzyme-replacement therapy in mucopolysaccharidosis I.
Kakkis ED; Muenzer J; Tiller GE; Waber L; Belmont J; Passage M; Izykowski B; Phillips J; Doroshow R; Walot I; Hoft R; Neufeld EF
N Engl J Med; 2001 Jan; 344(3):182-8. PubMed ID: 11172140
[TBL] [Abstract][Full Text] [Related]
10. [Alpha-L-iduronidase activity in fibroblasts of patients with Hurler syndrome].
Stareprawo G; Grimm U; Machill G; Knapp A; Wehnert M
Acta Biol Med Ger; 1975; 34(6):1079-82. PubMed ID: 812313
[No Abstract] [Full Text] [Related]
11. Impaired elastogenesis in Hurler disease: dermatan sulfate accumulation linked to deficiency in elastin-binding protein and elastic fiber assembly.
Hinek A; Wilson SE
Am J Pathol; 2000 Mar; 156(3):925-38. PubMed ID: 10702409
[TBL] [Abstract][Full Text] [Related]
12. alpha-L-iduronidase mutations (Q70X and P533R) associate with a severe Hurler phenotype.
Scott HS; Litjens T; Nelson PV; Brooks DA; Hopwood JJ; Morris CP
Hum Mutat; 1992; 1(4):333-9. PubMed ID: 1301941
[TBL] [Abstract][Full Text] [Related]
13. [Mucopolysaccharidosis V (Ullrich-Scheie syndrome) (author's transl)].
Kovarik J; Vormittag W; Gebhart W; Ruthner U; Lubec G; Molzer B
Wien Klin Wochenschr; 1978 Dec; 90(23):839-44. PubMed ID: 154210
[TBL] [Abstract][Full Text] [Related]
14. Enzyme replacement therapy in mucopolysaccharidosis I: altered distribution and targeting of alpha-L-iduronidase in immunized rats.
Turner CT; Hopwood JJ; Brooks DA
Mol Genet Metab; 2000 Apr; 69(4):277-85. PubMed ID: 10870845
[TBL] [Abstract][Full Text] [Related]
15. Mucopolysaccharidoses type I and IVA: clinical features and consanguinity in Tunisia.
Khedhiri S; Chkioua L; Bouzidi H; Dandana A; Ben Turkia H; Miled A; Laradi S
Pathol Biol (Paris); 2009 Jul; 57(5):392-7. PubMed ID: 18584975
[TBL] [Abstract][Full Text] [Related]
16. Mutation analysis of 19 North American mucopolysaccharidosis type I patients: identification of two additional frequent mutations.
Clarke LA; Nelson PV; Warrington CL; Morris CP; Hopwood JJ; Scott HS
Hum Mutat; 1994; 3(3):275-82. PubMed ID: 8019563
[TBL] [Abstract][Full Text] [Related]
17. Prevention of neuropathology in the mouse model of Hurler syndrome.
Desmaris N; Verot L; Puech JP; Caillaud C; Vanier MT; Heard JM
Ann Neurol; 2004 Jul; 56(1):68-76. PubMed ID: 15236403
[TBL] [Abstract][Full Text] [Related]
18. Mucopolysaccharidosis type V. (Scheie syndrome). A postmortem study by multidisciplinary techniques with emphasis on the brain.
Dekaban AS; Constantopoulos G; Herman MM; Steusing JK
Arch Pathol Lab Med; 1976 May; 100(5):237-45. PubMed ID: 817693
[TBL] [Abstract][Full Text] [Related]
19. c.1898C>G/p.Ser633Trp Mutation in Alpha-L-Iduronidase: Clinical and Structural Implications.
Peña-Gomar I; Jiménez-Mariscal JL; Cerón M; Rosas-Trigueros J; Reyes-López CA
Protein J; 2021 Feb; 40(1):68-77. PubMed ID: 33389473
[TBL] [Abstract][Full Text] [Related]
20. Ultrastructural analysis of dermal fibroblasts in mucopolysaccharidosis type I: Effects of enzyme replacement therapy and hematopoietic cell transplantation.
Cox-Brinkman J; van den Bergh Weerman MA; Wijburg FA; Aerts JM; Florquin S; van der Lee JH; Hollak CE
Ultrastruct Pathol; 2010 May; 34(3):126-32. PubMed ID: 20455661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
